Diabetic Neuropathic Pain is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Diabetic Neuropathic Pain have a 80% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Diabetic Neuropathic Pain compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diabetic Neuropathic Pain overview

Diabetic neuropathic pain arises from nerve damage due to prolonged high blood sugar levels in individuals with diabetes. It presents as tingling, burning, or shooting pain, often affecting the feet and legs, but can involve other body parts. This neuropathy disrupts nerve signaling, leading to heightened sensitivity or numbness. Diagnosis involves medical history, neurological exams, and sometimes nerve conduction tests. Management includes blood sugar control, medications targeting nerve pain, lifestyle adjustments, and pain management techniques. Addressing underlying diabetes and mitigating symptoms are crucial, as diabetic neuropathic pain can significantly impact daily life and quality of life for those affected.

For a complete picture of PTSR and LoA scores for drugs in Diabetic Neuropathic Pain, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.